Rouffy J, Chanu B, Bakir R, Goy-Loeper J, Djian F, Monsuez J J, Gomberg R, Laval-Jeantet M
Department of Internal Medicine and Vascular Pathology, Hôpital Saint-Louis, Paris, France.
Curr Med Res Opin. 1988;11(2):123-32. doi: 10.1185/03007998809110455.
Thirteen young adult patients suffering from heterozygotic familial hypercholesterolaemia with tendinous xanthomatosis, previously treated with a suitable special diet, were studied to assess the effect of bezafibrate, given for 2 years at a dose of 800 mg/day, on plasma lipid and lipoprotein levels and on changes in size of the Achilles tendon xanthomas. Measurements were made before and at intervals during treatment, the tendinous xanthomas being measured by an echographic procedure to give data on antero-posterior and lateral diameters, thus enabling an Achilles tendon index to be defined. The results confirm the hypolipidaemic activity of bezafibrate, changes in the levels of total cholesterol, triglycerides, lipids and lipoproteins (LDL, VLDL and HDL) being similar in direction and magnitude to those reported previously. A significant regression in the size of the Achilles tendon xanthomas was observed in 11 of the 13 patients, and the regression in the Achilles tendon index correlated significantly with a favourable change in the ratio HDL/LDL + VLDL. It is suggested that, as a result of this objective observation, a favourable effect of bezafibrate treatment would possibly be seen on the anatomical atheromatous lesions which are usual in this type of hyperlipidaemia.
对13例患有杂合子家族性高胆固醇血症并伴有肌腱黄色瘤的年轻成年患者进行了研究，这些患者之前接受过适当的特殊饮食治疗。给予他们苯扎贝特，剂量为800毫克/天，持续2年，以评估其对血脂和脂蛋白水平以及跟腱黄色瘤大小变化的影响。在治疗前及治疗期间定期进行测量，通过超声检查测量肌腱黄色瘤，以获取前后径和横径的数据，从而定义跟腱指数。结果证实了苯扎贝特的降血脂活性，总胆固醇、甘油三酯、脂质和脂蛋白（低密度脂蛋白、极低密度脂蛋白和高密度脂蛋白）水平的变化在方向和幅度上与之前报道的相似。13例患者中有11例观察到跟腱黄色瘤大小显著缩小，跟腱指数的缩小与高密度脂蛋白/低密度脂蛋白+极低密度脂蛋白比值的有利变化显著相关。据推测，基于这一客观观察结果，苯扎贝特治疗可能会对这类高脂血症中常见的动脉粥样硬化病变产生有利影响。
